Daiichi Sankyo Patent-Cliff Exposure & CMS Drug Spending Portfolio
Daiichi Sankyo (Basking Ridge, NJ): 12 reconciled FDA prescription therapies (12.6% 2025 to 2030 cliff risk), $371.9M 2024 CMS Part D & Medicaid spend, and 41 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Basking Ridge, NJ |
| Reconciled FDA Portfolio Therapies | 12 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 12.6% |
| Primary Portfolio LOE Date | 2028-01-01 |
| 2024 CMS Total Public Spend | $371.9M |
| 2024 Medicare Part D Spend | $26.2M |
| 2024 Medicaid Spend | $345.6M |
| California HCAI SB 17 Filings | 41 WAC filings (max 31.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.